ArticleMolecular & cellular proteomics : MCP2015
Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.
Article in Molecular & cellular proteomics : MCP, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 107 citations in OpenAlex.
- Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia.Cancer discovery · 2026Article
- A hierarchical lectin-based multimodal workflow for spatial mapping of extracellular matrix glycans in fibrotic hearts.Analytical and bioanalytical chemistry · 2026Article
- The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation.International journal of molecular sciences · 2026Review
- Article
- Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors.Cell reports. Medicine · 2025Article
- Global characterization of mouse testis O-glycoproteome landscape during spermatogenesis.Nature communications · 2025Article
- Deep crypt secretory cells shape region-specific mucin glycosylation patterns in the mouse colon.PloS one · 2025Article
- Glycosylation in Cancer.Handbook of experimental pharmacology · 2025Review
- Eph receptor signaling complexes in the plasma membrane.Trends in biochemical sciences · 2024Review
- Prediction of human O-linked glycosylation sites using stacked generalization and embeddings from pre-trained protein language model.Bioinformatics (Oxford, England) · 2024Article
- Article
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Sialyl-Tn glycan epitope as a target for pancreatic cancer therapies.Frontiers in oncology · 2024Article
- Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Truncation of GalNAc-type O-glycans Suppresses CD44-mediated Osteoclastogenesis and Bone Metastasis in Breast Cancer.Molecular cancer research : MCR · 2023Article
- Glycosylation Analysis of Urinary Peptidome Highlights IGF2 Glycopeptides in Association with CKD.International journal of molecular sciences · 2023Article
- CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies.Frontiers in immunology · 2023Review
- Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions.BMC cancer · 2022Article
- High-Throughput Glycomic Methods.Chemical reviews · 2022Review
- Development of a GalNAc-Tyrosine-Specific Monoclonal Antibody and Detection of TyrosineJournal of the American Chemical Society · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating O-glycoproteins shed from cancer cells represent important serum biomarkers for diagnostic and prognostic purposes. We have recently shown that selective detection of cancer-associated aberrant glycoforms of circulating O-glycoprotein biomarkers can increase specificity of cancer biomarker assays. However, the current knowledge of secreted and circulating O-glycoproteins is limited. Here, we used the COSMC KO "SimpleCell" (SC) strategy to characterize the O-glycoproteome of two gastric cancer SimpleCell lines (AGS, MKN45) as well as a gastric cell line (KATO III) which naturally expresses at least partially truncated O-glycans. Overall, we identified 499 O-glycoproteins and 1236 O-glycosites in gastric cancer SimpleCells, and a total 47 O-glycoproteins and 73 O-glycosites in the KATO III cell line. We next modified the glycoproteomic strategy to apply it to pools of sera from gastric cancer and healthy individuals to identify circulating O-glycoproteins with the STn glycoform. We identified 37 O-glycoproteins in the pool of cancer sera, and only nine of these were also found in sera from healthy individuals. Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. A proximity ligation assay was used to show that CD44 was expressed with the STn glycoform in gastric cancer tissues. The study provides a discovery strategy for aberrantly glycosylated O-glycoproteins and a set of O-glycoprotein candidates with biomarker potential in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.